Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 200 percent decrease over losses of $(0.05) per
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share. This is a 57.14 percent decrease over losses of $(0.07) per share from the same period last year.